Thursday 18 June 2026

The Pharma Letter Podcast — Episode 18 — Focus on rare liver diseases, with Albireo CEO Ron Cooper

Pharmaceutical
Simon Wentworth
31 October 2022
episode18-big

More on this story...

Biotechnology
Albireo shares rocket as study sets up second Bylvay approval
12 October 2022
Biotechnology
NICE backs NHS use of Albireo's Bylvay for all PFIC types
22 February 2022
Biotechnology
Albireo's Bylvay gets FDA green light for PFIC
21 July 2021
Pharmaceutical
Evaluate expects Roche to lead the way in steady pharma growth to 2028
21 October 2022




More ones to watch >




Today's issue

Sanofi’s Sarclisa SC wins MHRA backing
Biotechnology
Sanofi’s Sarclisa SC wins MHRA backing
18 June 2026
Pharmaceutical
FDA drug approvals rebound above decade average in 2025, says GlobalData
18 June 2026
Pharmaceutical
Curium court decision advances therapy plans for GEP-NETs
18 June 2026
Biotechnology
FDA accepts Roche’s sBLA for Lunsumio and Polivy combo
18 June 2026
Pharmaceutical
J-Pharma and Uniphar advance nanvuranlat into global Phase III trial
18 June 2026
Biosimilars
Samsung Bioepis and Organon expand commercialization of Pyzchiva
18 June 2026
Generics
First generic Xofluza clears US FDA ahead of flu season
18 June 2026


Company Spotlight

Edgewise Therapeutics
A Boulder, Colorado-based biotech that has sharpened its focus entirely on cardiovascular disease after divesting its muscular dystrophy franchise to Servier, with oral cardiac sarcomere modulator EDG-7500 now its singular Phase III-bound bet in hypertrophic cardiomyopathy.


More Features in Pharmaceutical

FDA drug approvals rebound above decade average in 2025, says GlobalData
18 June 2026
Curium court decision advances therapy plans for GEP-NETs
18 June 2026
J-Pharma and Uniphar advance nanvuranlat into global Phase III trial
18 June 2026
Neurizon locks in Elanco supply for ALS hopeful
18 June 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze